Sign in or register today for access to this and other blogs and discussions.
Paul Ridker discusses the Cardiovascular Inflammation Reduction Trial, which examines whether low-dose methotrexate can reduce cardiovascular events in patients with a prior MI and type 2 diabetes or metabolic syndrome. What do you think of this formal test of the inflammatory hypothesis?
CardioExchange is an online community hosted by the New England Journal of Medicine and Journal Watch and dedicated to improving cardiac patient care. Membership is free for medical professionals.